Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Introducing artificial intelligence for IVF directly at the point of care, revolutionizing the influence of extensive image and text data on business insights in reproductive medicine. We have gathered a team of the foremost specialists in artificial intelligence, IVF lab quality control/assurance, and digital technology solutions to develop this innovative platform, which boasts the largest open-source image database dedicated to embryology and andrology competency assessment globally. ART Compass emerges as the state-of-the-art IVF Lab Information Management System (LIMS), enhancing IVF lab quality management through artificial intelligence, all accessible via a user-friendly smartphone app. This platform allows for the evaluation of embryology and andrology competency assessments, as well as supports clinical decision-making in these fields. Users can also access annual procedure evaluation documentation, record new training for procedures, and onboard new staff seamlessly. Furthermore, it enables tracking of pregnancy outcomes for each IVF cycle while providing all necessary statistics. In addition, it facilitates management of patient cryostorage inventory and efficiently delivers preimplantation genetic testing results to physicians, ensuring a comprehensive approach to reproductive health. Ultimately, ART Compass is not just a tool; it represents a significant advancement in how IVF labs can operate and improve patient care.
Description
AarogyaAI is a software-as-a-service platform that utilizes artificial intelligence to identify drug-resistant tuberculosis (DR-TB) within hours. Our goal is to provide rapid and precise diagnoses of DR-TB, ensuring that patients receive the most effective drug combinations for their treatment without delay. Tuberculosis is responsible for more fatalities annually than AIDS, largely because the 19 available anti-TB medications do not work for all patients, leading to uncertainty among doctors regarding the appropriate treatment options. Consequently, even though tuberculosis is treatable, a delayed diagnosis of drug-resistant forms can result in patients remaining on ineffective medications for as long as seven years. By diagnosing drug-resistant tuberculosis swiftly, we enable prompt and appropriate treatment prescriptions. Patients upload a DNA sequence to our platform, and our advanced machine learning algorithm processes this data to generate a detailed report on drug susceptibility status, allowing healthcare providers to make informed decisions about treatment. This innovative approach not only enhances patient outcomes but also aims to reduce the overall burden of tuberculosis on healthcare systems.
API Access
Has API
API Access
Has API
Integrations
No details available.
Integrations
No details available.
Pricing Details
Free
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
ART Compass
Founded
2018
Country
United States
Website
artcompass.io
Vendor Details
Company Name
AarogyaAI
Country
India
Website
aarogya.ai/